Bone Biologics (BBLG) Projected to Announce Quarterly Earnings on Thursday

Bone Biologics (NASDAQ:BBLG) is expected to issue its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.39) per share for the quarter.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43). On average, analysts expect Bone Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Bone Biologics Stock Performance

NASDAQ:BBLG opened at $0.91 on Wednesday. Bone Biologics has a 1 year low of $0.83 and a 1 year high of $4.13. The stock has a fifty day moving average price of $1.21 and a two-hundred day moving average price of $1.27. The stock has a market capitalization of $1.64 million, a price-to-earnings ratio of -0.40 and a beta of 0.93.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its stake in Bone Biologics stock. DRW Securities LLC boosted its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 34.30% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a research note on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.